Home Featured Page 234

Featured

Latest

Colorado’s Psilocybin Supply Chain Complete: First Testing Lab Licensed, Sessions Could Begin This Month

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business...

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the...

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data...

Healing Trip Tales: One Vet’s Ibogaine & 5-MeO-DMT Experience for PTSD...

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities...

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative...

Virtual Reality and Psychedelic Synergy

Adding to their Expert Team, Albert Labs Announces the Formation and...

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat...

Silo Pharma Submits Application for NASDAQ up-listing

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing...

1...233234235...286 Page 234 of 286

Colorado’s Psilocybin Supply Chain Complete: First Testing Lab Licensed, Sessions Could...

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.